Imunon, Inc.(IMNN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMNN Imunon, Inc.

Not Yet Opened 06-03 16:00:00 EDT

2.10

-0.04

-1.87%

盘后2.12

+0.02+0.95%

19:59 EDT

High2.17	Low2.07	Vol34.11K
Open2.16	D1 Closing2.14	Amplitude4.67%
Mkt Cap8.82M	Tradable Cap8.02M	Total Shares4.20M
T/O72.37K	T/O Rate0.89%	Tradable Shares3.82M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMNN","market":"US","secType":"STK","nameCN":"Imunon, Inc.","latestPrice":2.1,"timestamp":1780516800000,"preClose":2.14,"halted":0,"volume":34105,"hourTrading":{"tag":"盘后","latestPrice":2.12,"preClose":2.1,"latestTime":"19:59 EDT","volume":3551,"amount":7511.0976,"timestamp":1780531192930,"change":0.02,"changeRate":0.009524,"amplitude":0.009524},"delay":0,"changeRate":-0.018691588785046745,"floatShares":3818399,"shares":4202100,"eps":-4.792268,"marketStatus":"Not Yet Opened","change":-0.04,"latestTime":"06-03 16:00:00 EDT","open":2.16,"high":2.17,"low":2.07,"amount":72374.28871,"amplitude":0.046729,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.792268,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780560000000},"marketStatusCode":0,"adr":0,"listingDate":959745600000,"exchange":"NASDAQ","adjPreClose":2.14,"preHourTrading":{"tag":"盘前","latestPrice":2.17,"preClose":2.14,"latestTime":"08:16 EDT","volume":152,"amount":329.6039136,"timestamp":1780488978231,"change":0.03,"changeRate":0.014019,"amplitude":0.009346},"postHourTrading":{"tag":"盘后","latestPrice":2.12,"preClose":2.1,"latestTime":"19:59 EDT","volume":3551,"amount":7511.0976,"timestamp":1780531192930,"change":0.02,"changeRate":0.009524,"amplitude":0.009524},"volumeRatio":0.486278},"requestUrl":"/m/hq/s/IMNN/wiki","defaultTab":"wiki","newsList":[{"id":"2635524099","title":"Analysts Are Bullish on Top Healthcare Stocks: Ovid Therapeutics (OVID), Imunon (IMNN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635524099","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635524099?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:10","pubTimestamp":1778616606,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ovid Therapeutics (OVID) and Imunon (IMNN) with bull...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-ovid-therapeutics-ovid-imunon-imnn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-ovid-therapeutics-ovid-imunon-imnn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BLSX","BK4585","BK4139","LU0029874061.USD","IMNN","BK4112","LU0128526141.USD","BK4137","BLSG","OVID","BK4588","XBI","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634219350","title":"Imunon Q1 net loss widens as R&D spending rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2634219350","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634219350?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:09","pubTimestamp":1778587755,"startTime":"0","endTime":"0","summary":"Imunon Q1 net loss widens as R&D spending risesOverviewU.S. biotech firm's Q1 net loss widened slightly as R&D spending increased for Phase 3 trialCompany advanced enrollment in pivotal Phase 3 OVATIO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL1N41P0M1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634219856","title":"Imunon Q1 FY26 net loss widens to $4.3 million; cash drops to $4.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634219856","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634219856?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:05","pubTimestamp":1778587503,"startTime":"0","endTime":"0","summary":"Imunon posted a first-quarter net loss of USD 4.3 million, or USD 0.84 per share, versus a net loss of USD 4.1 million, or USD 3.15 per share, a year earlier.Operating expenses rose to USD 4.3 million from USD 4.1 million, while R&D spending climbed to USD 2.3 million from USD 2.2 million.Net cash used in operating activities widened to USD 4 million from USD 2.8 million, reflecting trial-related costs tied to the Phase 3 OVATION 3 study.Cash and cash equivalents fell to USD 4.8 million as of March 31 from USD 8.8 million at year-end.Enrollment in OVATION 3 continued ahead of plan, with completion expected by Q1 2029; final Phase 2 OVATION 2 data showed median overall survival improved by 14.7 months to 45.1 months versus standard of care.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL4BVyDn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014039.USD","IMNN","LU2210149790.SGD","BK4588","LU2210150020.SGD","IE00BN0W2T93.GBP","NDAQ","LU0314104364.USD","IE00B64PRP62.GBP","BK4585","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4112","BK4139","IE00BN0W2V16.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634821641","title":"Imunon Q1 EPS $(0.84) Beats $(1.07) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634821641","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634821641?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:01","pubTimestamp":1778587271,"startTime":"0","endTime":"0","summary":"Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.07) by 21.5 percent. This is a 73.33 percent increase over losses of $(3.15) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52481872/imunon-q1-eps-0-84-beats-1-07-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216157","title":"Imunon Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216157?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA5VQYW3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634921643","title":"Imunon Q1 Operating Income USD -4.307 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634921643","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634921643?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXE44F46:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634161082","title":"Imunon Q1 EPS USD -0.84","url":"https://stock-news.laohu8.com/highlight/detail?id=2634161082","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634161082?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXE44F46:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMNN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634421903","title":"IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634421903","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634421903?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587200,"startTime":"0","endTime":"0","summary":"IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3292797/0/en/IMUNON-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634361463","title":"Imunon Inc  expected to post a loss of $1.11 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634361463","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634361463?lang=en_us&edition=fundamental","pubTime":"2026-05-09 00:08","pubTimestamp":1778256486,"startTime":"0","endTime":"0","summary":"Imunon Inc  expected to post a loss of $1.11 a share - Earnings Preview Imunon Inc IMNN.OQ IMNN.O is expected to  show no change in quarterly revenue when it reports  results on May 12 for the period ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L20C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633948461","title":"Imunon schedules first-quarter results, business update conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2633948461","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633948461?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:33","pubTimestamp":1777984406,"startTime":"0","endTime":"0","summary":"Imunon set conference call for May 12, 2026 at 11:00 a.m. EDT to report Q1 2026 financial results.Business update expected to cover Phase 3 development progress for lead ovarian cancer candidate IMNN-001.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL1TW83G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","SG9999014005.SGD","LU0314104364.USD","IE00BN0W2W23.USD","SG9999014039.USD","BK4588","IMNN","BK4139","BK4585","SG9999014013.SGD","NDAQ","BK4112","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014021.USD","IE00BGHQF748.EUR","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633948401","title":"IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633948401","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633948401?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:30","pubTimestamp":1777984200,"startTime":"0","endTime":"0","summary":"LAWRENCEVILLE, N.J., May  05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company w","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287688/0/en/IMUNON-to-Hold-First-Quarter-2026-Financial-Results-and-Business-Update-Conference-Call-on-Tuesday-May-12-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632958280","title":"Imunon adopts change-of-control severance agreements for top executives","url":"https://stock-news.laohu8.com/highlight/detail?id=2632958280","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632958280?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:04","pubTimestamp":1777896294,"startTime":"0","endTime":"0","summary":"Imunon entered change-of-control severance agreements on May 1, 2026 covering CEO and President Stacy Lindborg, Chief Medical Officer Douglas Faller, General Counsel Susan Eylward.Termination without cause or resignation for good reason within one year after or four months before a change in control triggers lump-sum severance of 2.5x base salary plus target annual bonus for Lindborg, 1.5x for other covered executives.Benefits also include company-paid or reimbursed COBRA health premiums and life insurance for up to 24 months for Lindborg, up to 18 months for other executives.Agreements provide full acceleration of outstanding equity awards, with options generally remaining exercisable for original term subject to specified limits for post-change-in-control vesting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL24zWnQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632932640","title":"Imunon announces annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2632932640","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632932640?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:33","pubTimestamp":1777890808,"startTime":"0","endTime":"0","summary":"Imunon schedules virtual annual shareholder meeting on June 16, 2026.Shareholders set to vote on election of two Class I directors with terms running to 2029.Ballot also includes ratification of WithumSmith+Brown PC as independent registered public accounting firm for fiscal 2026.Additional items include advisory vote on 2025 executive compensation plus amendment to 2018 Stock Incentive Plan to raise share reserve by 1,000,000 to 1,265,004.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 04, 2026, and is solely responsible for","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL28k2gL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628201075","title":"Imunon Initiated at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2628201075","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628201075?lang=en_us&edition=fundamental","pubTime":"2026-04-17 21:28","pubTimestamp":1776432480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMNN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 17, 2026 09:28 ET (13:28 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628746209","title":"Imunon initiated with a Buy at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2628746209","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628746209?lang=en_us&edition=fundamental","pubTime":"2026-04-17 20:46","pubTimestamp":1776429987,"startTime":"0","endTime":"0","summary":"Maxim initiated coverage of Imunon (IMNN) with a Buy rating and $10 price target Published first on TheFly – the ultimate source for real-time, mar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/imunon-initiated-with-a-buy-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/imunon-initiated-with-a-buy-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624570485","title":"Analysts Offer Insights on Healthcare Companies: Imunon (IMNN), Axsome Therapeutics (AXSM) and Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624570485","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624570485?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:20","pubTimestamp":1775125212,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Imunon (IMNN), Axsome Therapeutics (AXSM) and Oric P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-imunon-imnn-axsome-therapeutics-axsm-and-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-imunon-imnn-axsome-therapeutics-axsm-and-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC","LABU","BK4585","XLV","BK4137","BK4581","LU0029874061.USD","XBI","HCSG","LU0128526141.USD","BK4007","BK4139","AXSM","IMNN","BK4505","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624379511","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Imunon (IMNN) and Novo Nordisk (NVO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624379511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624379511?lang=en_us&edition=fundamental","pubTime":"2026-04-01 21:30","pubTimestamp":1775050208,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Imunon (IMNN) and Novo Nordisk (NVO). Imunon (IMNN) Alliance Glob...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-imunon-imnn-and-novo-nordisk-nvo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-imunon-imnn-and-novo-nordisk-nvo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","LU0029874061.USD","NVO","LU0128526141.USD","XBI","IE00BKVL7J92.USD","BK4139","BK4581","BK4588","LU1093756168.USD","NVOH","IMNN","BK4585","LU0154236417.USD","BK4599","IE00BZ1G4Q59.USD","NVOX","LU1093756325.SGD","BK4532","BK4007","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624306555","title":"Imunon FY25 net loss narrows 22% to $14.5 million; cash climbs to $8.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624306555","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624306555?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:31","pubTimestamp":1774992719,"startTime":"0","endTime":"0","summary":"R&D expense dropped 33% to $7.8 million on lower OVATION 2 and PlaCCine trial costs, partly offset by OVATION 3 start-up spending.Cash and cash equivalents rose to $8.8 million at year-end.Final Phase 2 OVATION 2 data showed median overall survival improved by 14.7 months to 45.1 months with IMNN-001 versus standard chemotherapy alone.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL5DYbdh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623581929","title":"BRIEF-Imunon Reports 2025 Financial Results And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623581929","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623581929?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:40","pubTimestamp":1774960822,"startTime":"0","endTime":"0","summary":"BRIEF-Imunon Reports 2025 Financial Results And Provides Business Update March 31 (Reuters) - Imunon Inc IMNN.O:IMUNON REPORTS 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE HIGHLIGHTING SIGNIFIC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUABJRPQS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623589574","title":"Imunon Q4 EPS $(1.30) Misses $(1.13) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2623589574","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623589574?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:12","pubTimestamp":1774959155,"startTime":"0","endTime":"0","summary":"Imunon (NASDAQ:IMNN) reported quarterly losses of $(1.30) per share which missed the analyst consensus estimate of $(1.13) by 15.04 percent. This is a 56.67 percent increase over losses of $(3.00) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51564288/imunon-q4-eps-1-30-misses-1-13-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.imunon.com","stockEarnings":[{"period":"1week","weight":-0.0273},{"period":"1month","weight":-0.2357},{"period":"3month","weight":-0.3815},{"period":"6month","weight":-0.465},{"period":"1year","weight":-0.9346},{"period":"ytd","weight":-0.4383}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.054},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.1098},{"period":"1year","weight":0.2815},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.411765,"avgChangeRate":0.082435},{"month":2,"riseRate":0.363636,"avgChangeRate":0.03006},{"month":3,"riseRate":0.5,"avgChangeRate":0.046462},{"month":4,"riseRate":0.323529,"avgChangeRate":-0.048114},{"month":5,"riseRate":0.342857,"avgChangeRate":0.114856},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.050523},{"month":7,"riseRate":0.382353,"avgChangeRate":-0.054834},{"month":8,"riseRate":0.411765,"avgChangeRate":0.007426},{"month":9,"riseRate":0.294118,"avgChangeRate":-0.078238},{"month":10,"riseRate":0.294118,"avgChangeRate":-0.043613},{"month":11,"riseRate":0.294118,"avgChangeRate":-0.024039},{"month":12,"riseRate":0.441176,"avgChangeRate":-0.041409}],"exchange":"NASDAQ","name":"Imunon, Inc.","nameEN":"Imunon, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Imunon, Inc.(IMNN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Imunon, Inc.(IMNN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Imunon, Inc.,IMNN,Imunon, Inc.股票,Imunon, Inc.股票老虎,Imunon, Inc.股票老虎国际,Imunon, Inc.行情,Imunon, Inc.股票行情,Imunon, Inc.股价,Imunon, Inc.股市,Imunon, Inc.股票价格,Imunon, Inc.股票交易,Imunon, Inc.股票购买,Imunon, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Imunon, Inc.(IMNN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Imunon, Inc.(IMNN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction